- Well-known and recognized Onco-Surgeon of India
- Performed more than 12000 cancer surgeries including Breast, Thoracic, Gastro-Intestinal & Hepatobilliary Surgeries
- Trained in Laparoscopic Cancer Surgeries
- Expertise’s in Breast, Thoracic (Lung & Oesophagus), Gastro-Intestinal, Colo-rectal & Hepatobilliary Surgeries, Bone and Soft Tissue Cancer Surgeries and Laparoscopic (Minimally Invasive) Cancer Surgeries
- Member of various renowned organizations such as Delhi Medical Association (DMA) and Indian Medical Association (IMA)
Dr. Niranjan Naik
- Surgical Oncologist
- Director , MBBS, MS, 21 years of experience
- Fortis Memorial Research Institute
- Gurgaon


Dr. Niranjan Naik
- Surgical Oncologist
- Director , MBBS, MS, 21 years of experience
- Fortis Memorial Research Institute
- Gurgaon
Profile (Overview)
Specialization
- Breast
- Thoracic (Lung & Oesophagus)
- Gastro-Intestinal
- Colo-rectal & Hepatobilliary Surgeries
- Bone and Soft Tissue Cancer Surgeries and Laparoscopic (Minimally Invasive) Cancer Surgeries
Work Experience of Dr. Niranjan Naik
- Senior Consultant, Dharamshila Narayana Superspeciality Hospital , New Delhi
- Consultant, Mool Chand KR Hospital, Lajpat Nagar -III , 2004
- Consultant, Mata Chanan Devi Hospital, Janakpuri , 2004
- Consultant, Kailash Hospital, NOIDA , 2004
Education
- MBBS, 1992, Bangalore Medical College, Bangalore
- MS, 1996, All India Institute of Medical Sciences, New Delhi
Awards
Paper Published
- Symptomatic outcome after Laparoscopic Cholecystectomy. (Prospective study of 113 patients undergoing laparoscopic cholecystectomy).
- INVESIGATOR IN PHASE III CLINICAL TRIAL:Comparative PK, Efficacy, Safety and Immunogenicity evaluation of Bmab-200 versus Herceptin®, both in combination with Docetaxel in patients with Her2+ Metastatic Breast Cancer: A Double-Blind, Randomised, Active Control, Parallel Assignment, Comparative Phase III Clinical Trial.
- GUIDE IN DIPLOMATE OF NATIONAL BOARD (DNB) SURGICAL ONCOLOGY THESIS: The role of {18F} FDG PET Scan in evaluation of clinic-pathological response of neo-adjuvant chemotherapy in locally advanced breast cancer, Chief guide, 2014-2017